Related Experiment Video

Updated: Jun 22, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors

Biqing Chen1, Jiaqi Liu1

  • 1The Second Hospital of Jilin University, Changchun, China.

Current Cancer Drug Targets
|July 5, 2024
PubMed

Insights

Cyclin-dependent Kinase 12 (CDK12) is vital for gene expression and DNA repair. Targeting CDK12 shows promise for inhibiting tumor growth and developing new cancer therapies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Cyclin-dependent Kinase 12 (CDK12) regulates critical cellular processes like transcription, DNA repair, and cell cycle progression.
  • CDK12 dysregulation and genetic alterations are linked to various cancers, including breast, ovarian, gastric, and prostate cancers.

Purpose of the Study:

  • To review the multifaceted roles of CDK12 in gene expression and its implications in human tumorigenesis.
  • To highlight CDK12 as a significant cancer biomarker and a promising therapeutic target for cancer treatment.

Main Methods:

  • Literature review of studies on CDK12 functions, genetic alterations in cancer, and therapeutic strategies.
  • Examination of recent advancements in developing CDK12 inhibitors (e.g., PROTAC, molecular gel degraders) and combination therapies.

Main Results:

  • CDK12 plays a key role in modulating gene expression and is implicated in the development of multiple human tumors.
  • Suppression of CDK12 effectively inhibits tumor growth and proliferation, validating its role in cancer progression.

Conclusions:

  • Understanding CDK12's functions is crucial for advancing novel cancer treatment and prevention strategies.
  • Emerging therapeutic approaches targeting CDK12, including small molecule inhibitors and combination therapies with immunotherapy, show significant potential for cancer management.
Keywords:
CDK12CancerPROTAC.cancer biomarkerinhibitorsmolecular structuresignaling pathways

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K